Details for New Drug Application (NDA): 022254
✉ Email this page to a colleague
The generic ingredient in VIMPAT is lacosamide. There are twenty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
Summary for 022254
Tradename: | VIMPAT |
Applicant: | Ucb Inc |
Ingredient: | lacosamide |
Patents: | 0 |
Pharmacology for NDA: 022254
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 022254
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
VIMPAT | lacosamide | SOLUTION;INTRAVENOUS | 022254 | NDA | UCB, Inc. | 0131-1810 | 0131-1810-67 | 10 VIAL, GLASS in 1 CARTON (0131-1810-67) / 20 mL in 1 VIAL, GLASS |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 200MG/20ML (10MG/ML) | ||||
Approval Date: | Oct 28, 2008 | TE: | AP | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | Oct 14, 2024 | ||||||||
Regulatory Exclusivity Use: | NEW PATIENT POPULATION | ||||||||
Regulatory Exclusivity Expiration: | Apr 28, 2026 | ||||||||
Regulatory Exclusivity Use: | USE OF ALTERNATE INITIAL DOSING REGIMEN FOR INITIATION OF LACOSAMIDE TREATMENT IN PARTIAL ONSET SEIZURE PATIENTS ≥1 MONTH TO |
Expired US Patents for NDA 022254
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ucb Inc | VIMPAT | lacosamide | SOLUTION;INTRAVENOUS | 022254-001 | Oct 28, 2008 | 5,654,301 | ⤷ Subscribe |
Ucb Inc | VIMPAT | lacosamide | SOLUTION;INTRAVENOUS | 022254-001 | Oct 28, 2008 | RE38551 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription